Despite the promising preclinical work, experience in human pituitary tumors is limited to an isolated report of unsuccessful treatment with everolimus in a single patient with a pituitary carcinoma (a rare entity defined by presence of metastasis), and as such, no clear conclusions can be made about efficacy of PI3K/Akt/mTOR inhibition in human pituitary tumors (117). This evidence concerns the gene AKT1 and pituitary tumor.